Chapter 7 The Regulation of Protein Synthesis in Cancer

Progress in Molecular Biology and Translational Science

Volumn 90, Issue C, 2009, Pages 255-292

  Cuesta, Rafael ^a   Gupta, Malavika ^a   Schneider, Robert J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Clinical trials; Protein synthesis; Signal transduction; Translational control

Indexed keywords

INITIATION FACTOR 3;

ANIMAL; DISEASE COURSE; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PRECANCER; PROTEIN SYNTHESIS; REVIEW; RIBOSOME; SIGNAL TRANSDUCTION; UNTRANSLATED REGION;

ANIMALS; DISEASE PROGRESSION; EUKARYOTIC INITIATION FACTOR-3; HUMANS; NEOPLASMS; PRECANCEROUS CONDITIONS; PROTEIN BIOSYNTHESIS; RIBOSOMES; SIGNAL TRANSDUCTION; UNTRANSLATED REGIONS;

EID: 77957042196     PISSN: 18771173     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1877-1173(09)90007-2     Document Type: Review

References (235)

1. Pianese G. Beitrag zur histologie und Aetiologie der carcinoma histologische und experimentelle. Beitr Pathol Anat Allgem Pathol 142 (1896) 1-193
2. Johnson L.F., Levis R., Abelson H.T., Green H., and Penman S. Changes in RNA in relation to growth of the fibroblast. IV. Alterations in the production and processing of mRNA and rRNA in resting and growing cells. J Cell Biol 71 (1976) 933-938
3. Baxter G.C., and Stanners C.P. The effect of protein degradation on cellular growth characteristics. J Cell Physiol 96 (1978) 139-145
4. Zetterberg A., Larsson O., and Wiman K.G. What is the restriction point?. Curr Opin Cell Biol 7 (1995) 835-842
5. Stanners C.P., Adams M.E., Harkins J.L., and Pollard J.W. Transformed cells have lost control of ribosome number through their growth cycle. J Cell Physiol 100 (1979) 127-138
6. Buttgereit F., and Brand M.D. A hierarchy of ATP-consuming processes in mammalian cells. Biochem J 312 Pt 1 (1995) 163-167
7. Culjkovic B., Topisirovic I., and Borden K.L. Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E. Cell Cycle 6 (2007) 65-69
8. Pesole G., Mignone F., Gissi C., Grillo G., Licciulli F., and Liuni S. Structural and functional features of eukaryotic mRNA untranslated regions. Gene 276 (2001) 73-81
9. De Benedetti A., and Graff J.R. eIF-4E expression and its role in malignancies and metastases. Oncogene 23 (2004) 3189-3199
10. Kerekatte V., Smiley K., Hu B., Smith A., Gelder F., and De Benedetti A. The proto-oncogene/translation factor eIF4E: a survey of its expression in breast carcinomas. Int J Cancer 64 (1995) 27-31
11. Rosenwald I.B., Chen J.J., Wang S., Savas L., London I.M., and Pullman J. Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 18 (1999) 2507-2517
12. Rosenwald I.B., Hutzler M.J., Wang S., Savas L., and Fraire A.E. Expression of eukaryotic translation initiation factors 4E and 2 alpha is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung. Cancer 92 (2001) 2164-2171
13. Schneider R.J., and Sonenberg N. Translational control in cancer development and progression. In: Mathews M.B., Sonenberg N., and Hershey J.W.B. (Eds). Translational control in biology and medicine (2007), Cold Spring Harbor Press, Cold Spring Harbor 401-432
14. Graff J.R., Konicek B.W., Carter J.H., and Marcusson E.G. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 68 (2008) 631-634
15. Graff J.R., Konicek B.W., Lynch R.L., Dumstorf C.A., Dowless M.S., McNulty A.M., et al. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res 69 (2009) 3866-3873
16. Sonenberg N. eIF4E, the mRNA cap-binding protein: from basic discovery to translational research. Biochem Cell Biol 86 (2008) 178-183
17. Thumma S.C., and Kratzke R.A. Translational control: a target for cancer therapy. Cancer Lett 258 (2007) 1-8
18. Lazaris-Karatzas A., Montine K.S., and Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 345 (1990) 544-547
19. Zimmer S.G., DeBenedetti A., and Graff J.R. Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 20 (2000) 1343-1351
20. Ruggero D., Montanaro L., Ma L., Xu W., Londei P., Cordon-Cardo C., et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 10 (2004) 484-486
21. Wendel H.G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428 (2004) 332-337
22. Lazaris-Karatzas A., Smith M.R., Frederickson R.M., Jaramillo M.L., Liu Y.L., Kung H.F., et al. Ras mediates translation initiation factor 4E-induced malignant transformation. Genes Dev 6 (1992) 1631-1642
23. Rinker-Schaeffer C.W., Graff J.R., De Benedetti A., Zimmer S.G., and Rhoads R.E. Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. Int J Cancer 55 (1993) 841-847
24. Oridate N., Kim H.J., Xu X., and Lotan R. Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin. Cancer Biol Ther 4 (2005) 318-323
25. Koromilas A.E., Lazaris-Karatzas A., and Sonenberg N. mRNAs containing extensive secondary structure in their 5′ non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E. EMBO J 11 (1992) 4153-4158
26. Graff J.R., Boghaert E.R., De Benedetti A., Tudor D.L., Zimmer C.C., Chan S.K., et al. Reduction of translation initiation factor 4E decreases the malignancy of ras-transformed cloned rat embryo fibroblasts. Int J Cancer 60 (1995) 255-263
27. Rousseau D., Gingras A.C., Pause A., and Sonenberg N. The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 13 (1996) 2415-2420
28. Avdulov S., Li S., Michalek V., Burrichter D., Peterson M., Perlman D.M., et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5 (2004) 553-563
29. Herbert T.P., Fahraeus R., Prescott A., Lane D.P., and Proud C.G. Rapid induction of apoptosis mediated by peptides that bind initiation factor eIF4E. Curr Biol 10 (2000) 793-796
30. Armengol G., Rojo F., Castellvi J., Iglesias C., Cuatrecasas M., Pons B., et al. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 67 (2007) 7551-7555
31. Bordeleau M.E., Robert F., Gerard B., Lindqvist L., Chen S.M., Wendel H.G., et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 118 (2008) 2651-2660
32. Coleman L.J., Peter M.B., Teall T.J., Brannan R.A., Hanby A.M., Honarpisheh H., et al. Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer 100 (2009) 1393-1399
33. Salehi Z., and Mashayekhi F. Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer. Clin Biochem 39 (2006) 404-409
34. Braunstein S., Karpisheva K., Pola C., Goldberg J., Hochman T., Yee H., et al. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell 28 (2007) 501-512
35. Fukuchi-Shimogori T., Ishii I., Kashiwagi K., Mashiba H., Ekimoto H., and Igarashi K. Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res 57 (1997) 5041-5044
36. Comtesse N., Keller A., Diesinger I., Bauer C., Kayser K., Huwer H., et al. Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26-27 in squamous cell carcinoma of the lung. Int J Cancer 120 (2007) 2538-2544
37. Bauer C., Brass N., Diesinger I., Kayser K., Grasser F.A., and Meese E. Overexpression of the eukaryotic translation initiation factor 4G (eIF4G-1) in squamous cell lung carcinoma. Int J Cancer 98 (2002) 181-185
38. Bauer C., Diesinger I., Brass N., Steinhart H., Iro H., and Meese E.U. Translation initiation factor eIF-4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma. Cancer 92 (2001) 822-829
39. Brass N., Heckel D., Sahin U., Pfreundschuh M., Sybrecht G.W., and Meese E. Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma. Hum Mol Genet 6 (1997) 33-39
40. Silvera D., Arju R., Darvishian F., Levine P.H., Zolfaghari L., Goldberg J., et al. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol 11 (2009) 903-908
41. Wang X., Yu J., Sreekumar A., Varambally S., Shen R., Giacherio D., et al. Autoantibody signatures in prostate cancer. N Engl J Med 353 (2005) 1224-1235
42. Shuda M., Kondoh N., Tanaka K., Ryo A., Wakatsuki T., Hada A., et al. Enhanced expression of translation factor mRNAs in hepatocellular carcinoma. Anticancer Res 20 (2000) 2489-2494
43. Cencic R., Carrier M., Galicia-Vazquez G., Bordeleau M.E., Sukarieh R., Bourdeau A., et al. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS One 4 (2009) e5223
44. Lankat-Buttgereit B., and Goke R. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biol Cell 101 (2009) 309-317
45. Yang H.S., Jansen A.P., Komar A.A., Zheng X., Merrick W.C., Costes S., et al. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol 23 (2003) 26-37
46. Dong Z., and Zhang J.T. Initiation factor eIF3 and regulation of mRNA translation, cell growth, and cancer. Crit Rev Oncol Hematol 59 (2006) 169-180
47. Zhang L., Pan X., and Hershey J.W. Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast cells. J Biol Chem 282 (2007) 5790-5800
48. Bachmann F., Banziger R., and Burger M.M. Cloning of a novel protein overexpressed in human mammary carcinoma. Cancer Res 57 (1997) 988-994
49. Dellas A., Torhorst J., Bachmann F., Banziger R., Schultheiss E., and Burger M.M. Expression of p150 in cervical neoplasia and its potential value in predicting survival. Cancer 83 (1998) 1376-1383
50. Pincheira R., Chen Q., and Zhang J.T. Identification of a 170-kDa protein over-expressed in lung cancers. Br J Cancer 84 (2001) 1520-1527
51. Chen G., and Burger M.M. p150 expression and its prognostic value in squamous-cell carcinoma of the esophagus. Int J Cancer 84 (1999) 95-100
52. Chen G., and Burger M.M. p150 overexpression in gastric carcinoma: the association with p53, apoptosis and cell proliferation. Int J Cancer 112 (2004) 393-398
53. Dong Z., Liu L.H., Han B., Pincheira R., and Zhang J.T. Role of eIF3 p170 in controlling synthesis of ribonucleotide reductase M2 and cell growth. Oncogene 23 (2004) 3790-3801
54. Dong Z., and Zhang J.T. EIF3 p170, a mediator of mimosine effect on protein synthesis and cell cycle progression. Mol Biol Cell 14 (2003) 3942-3951
55. Rothe M., Ko Y., Albers P., and Wernert N. Eukaryotic initiation factor 3 p110 mRNA is overexpressed in testicular seminomas. Am J Pathol 157 (2000) 1597-1604
56. Scoles D.R., Yong W.H., Qin Y., Wawrowsky K., and Pulst S.M. Schwannomin inhibits tumorigenesis through direct interaction with the eukaryotic initiation factor subunit c (eIF3c). Hum Mol Genet 15 (2006) 1059-1070
57. Nupponen N.N., Porkka K., Kakkola L., Tanner M., Persson K., Borg A., et al. Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol 154 (1999) 1777-1783
58. Saramaki O., Willi N., Bratt O., Gasser T.C., Koivisto P., Nupponen N.N., et al. Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am J Pathol 159 (2001) 2089-2094
59. Cappuzzo F., Varella-Garcia M., Rossi E., Gajapathy S., Valente M., Drabkin H., et al. MYC and EIF3H coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib. J Thorac Oncol 4 (2009) 472-478
60. Shi J., Kahle A., Hershey J.W., Honchak B.M., Warneke J.A., Leong S.P., et al. Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells. Oncogene 25 (2006) 4923-4936
61. Doldan A., Chandramouli A., Shanas R., Bhattacharyya A., Leong S.P., Nelson M.A., et al. Loss of the eukaryotic initiation factor 3f in melanoma. Mol Carcinog 47 (2008) 806-813
62. Doldan A., Chandramouli A., Shanas R., Bhattacharyya A., Cunningham J.T., Nelson M.A., et al. Loss of the eukaryotic initiation factor 3f in pancreatic cancer. Mol Carcinog 47 (2008) 235-244
63. Marchetti A., Buttitta F., Pellegrini S., Bertacca G., and Callahan R. Reduced expression of INT-6/eIF3-p48 in human tumors. Int J Oncol 18 (2001) 175-179
64. Umar A., Kang H., Timmermans A.M., Look M.P., Meijer-van Gelder M.E., den Bakker M.A., et al. Identification of a putative protein profile associating with tamoxifen therapy-resistance in breast cancer. Mol Cell Proteomics 8 (2009) 1278-1294
65. Proud C.G. eIF2 and the control of cell physiology. Semin Cell Dev Biol 16 (2005) 3-12
66. Ron D. Translational control in the endoplasmic reticulum stress response. J Clin Invest 110 (2002) 1383-1388
67. Harding H.P., Novoa I., Zhang Y., Zeng H., Wek R., Schapira M., et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell 6 (2000) 1099-1108
68. Chen J.J. Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: relevance to anemias. Blood 109 (2007) 2693-2699
69. Koromilas A.E., Roy S., Barber G.N., Katze M.G., and Sonenberg N. Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. Science 257 (1992) 1685-1689
70. Donze O., Jagus R., Koromilas A.E., Hershey J.W., and Sonenberg N. Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells. EMBO J 14 (1995) 3828-3834
71. Sequeira S.J., Ranganathan A.C., Adam A.P., Iglesias B.V., Farias E.F., and Aguirre-Ghiso J.A. Inhibition of proliferation by PERK regulates mammary acinar morphogenesis and tumor formation. PLoS One 2 (2007) e615
72. Pervin S., Tran A.H., Zekavati S., Fukuto J.M., Singh R., and Chaudhuri G. Increased susceptibility of breast cancer cells to stress mediated inhibition of protein synthesis. Cancer Res 68 (2008) 4862-4874
73. Thomas C.G., and Spyrou G. ERdj5 sensitizes neuroblastoma cells to endoplasmic reticulum stress-induced apoptosis. J Biol Chem 284 (2009) 6282-6290
74. Barber G.N., Wambach M., Thompson S., Jagus R., and Katze M.G. Mutants of the RNA-dependent protein kinase (PKR) lacking double-stranded RNA binding domain I can act as transdominant inhibitors and induce malignant transformation. Mol Cell Biol 15 (1995) 3138-3146
75. Meurs E.F., Galabru J., Barber G.N., Katze M.G., and Hovanessian A.G. Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 90 (1993) 232-236
76. Abraham N., Stojdl D.F., Duncan P.I., Methot N., Ishii T., Dube M., et al. Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR. J Biol Chem 274 (1999) 5953-5962
77. Yang Y.L., Reis L.F., Pavlovic J., Aguzzi A., Schafer R., Kumar A., et al. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J 14 (1995) 6095-6106
78. Haines III G.K., Becker S., Ghadge G., Kies M., Pelzer H., and Radosevich J.A. Expression of the double-stranded RNA-dependent protein kinase (p68) in squamous cell carcinoma of the head and neck region. Arch Otolaryngol Head Neck Surg 119 (1993) 1142-1147
79. Haines G.K., Ghadge G.D., Becker S., Kies M., Pelzer H., Thimmappaya B., et al. Correlation of the expression of double-stranded RNA-dependent protein kinase (p68) with differentiation in head and neck squamous cell carcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol 63 (1993) 289-295
80. Haines III G.K., Panos R.J., Bak P.M., Brown T., Zielinski M., Leyland J., et al. Interferon-responsive protein kinase (p68) and proliferating cell nuclear antigen are inversely distributed in head and neck squamous cell carcinoma. Tumour Biol 19 (1998) 52-59
81. Terada T., Maeta H., Endo K., and Ohta T. Protein expression of double-stranded RNA-activated protein kinase in thyroid carcinomas: correlations with histologic types, pathologic parameters, and Ki-67 labeling. Hum Pathol 31 (2000) 817-821
82. Beretta L., Gabbay M., Berger R., Hanash S.M., and Sonenberg N. Expression of the protein kinase PKR in modulated by IRF-1 and is reduced in 5q-associated leukemias. Oncogene 12 (1996) 1593-1596
83. Shimada A., Shiota G., Miyata H., Kamahora T., Kawasaki H., Shiraki K., et al. Aberrant expression of double-stranded RNA-dependent protein kinase in hepatocytes of chronic hepatitis and differentiated hepatocellular carcinoma. Cancer Res 58 (1998) 4434-4438
84. Kim S.H., Forman A.P., Mathews M.B., and Gunnery S. Human breast cancer cells contain elevated levels and activity of the protein kinase, PKR. Oncogene 19 (2000) 3086-3094
85. Haines G.K., Cajulis R., Hayden R., Duda R., Talamonti M., and Radosevich J.A. Expression of the double-stranded RNA-dependent protein kinase (p68) in human breast tissues. Tumour Biol 17 (1996) 5-12
86. Tejada S., Lobo M.V., Garcia-Villanueva M., Sacristan S., Perez-Morgado M.I., Salinas M., et al. Eukaryotic initiation factors (eIF) 2alpha and 4E expression, localization, and phosphorylation in brain tumors. J Histochem Cytochem 57 (2009) 503-512
87. Bi M., Naczki C., Koritzinsky M., Fels D., Blais J., Hu N., et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J 24 (2005) 3470-3481
88. Koritzinsky M., Magagnin M.G., van den Beucken T., Seigneuric R., Savelkouls K., Dostie J., et al. Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J 25 (2006) 1114-1125
89. Koritzinsky M., Rouschop K.M., van den Beucken T., Magagnin M.G., Savelkouls K., Lambin P., et al. Phosphorylation of eIF2alpha is required for mRNA translation inhibition and survival during moderate hypoxia. Radiother Oncol 83 (2007) 353-361
90. Koritzinsky M., and Wouters B.G. Hypoxia and regulation of messenger RNA translation. Methods Enzymol 435 (2007) 247-273
91. Wouters B.G., and Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8 (2008) 851-864
92. Schewe D.M., and Aguirre-Ghiso J.A. Inhibition of eIF2{alpha} dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res 69 (2009) 1545-1552
93. Carmo-Fonseca M., Mendes-Soares L., and Campos I. To be or not to be in the nucleolus. Nat Cell Biol 2 (2000) E107-E112
94. Tschochner H., and Hurt E. Pre-ribosomes on the road from the nucleolus to the cytoplasm. Trends Cell Biol 13 (2003) 255-263
95. Derenzini M., Trere D., Pession A., Govoni M., Sirri V., and Chieco P. Nucleolar size indicates the rapidity of cell proliferation in cancer tissues. J Pathol 191 (2000) 181-186
96. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60 (2000) 3689-3695
97. Grummt I. Regulation of mammalian ribosomal gene transcription by RNA polymerase I. Prog Nucleic Acid Res Mol Biol 62 (1999) 109-154
98. Klein J., and Grummt I. Cell cycle-dependent regulation of RNA polymerase I transcription: the nucleolar transcription factor UBF is inactive in mitosis and early G1. Proc Natl Acad Sci USA 96 (1999) 6096-6101
99. Pyronnet S., and Sonenberg N. Cell-cycle-dependent translational control. Curr Opin Genet Dev 11 (2001) 13-18
100. Heix J., Vente A., Voit R., Budde A., Michaelidis T.M., and Grummt I. Mitotic silencing of human rRNA synthesis: inactivation of the promoter selectivity factor SL1 by cdc2/cyclin B-mediated phosphorylation. EMBO J 17 (1998) 7373-7381
101. Leung A.K., Gerlich D., Miller G., Lyon C., Lam Y.W., Lleres D., et al. Quantitative kinetic analysis of nucleolar breakdown and reassembly during mitosis in live human cells. J Cell Biol 166 (2004) 787-800
102. Sirri V., Roussel P., and Hernandez-Verdun D. In vivo release of mitotic silencing of ribosomal gene transcription does not give rise to precursor ribosomal RNA processing. J Cell Biol 148 (2000) 259-270
103. Pardee A.B. G1 events and regulation of cell proliferation. Science 246 (1989) 603-608
104. Voit R., Kuhn A., Sander E.E., and Grummt I. Activation of mammalian ribosomal gene transcription requires phosphorylation of the nucleolar transcription factor UBF. Nucleic Acids Res 23 (1995) 2593-2599
105. Voit R., and Grummt I. Phosphorylation of UBF at serine 388 is required for interaction with RNA polymerase I and activation of rDNA transcription. Proc Natl Acad Sci USA 98 (2001) 13631-13636
106. Voit R., Schnapp A., Kuhn A., Rosenbauer H., Hirschmann P., Stunnenberg H.G., et al. The nucleolar transcription factor mUBF is phosphorylated by casein kinase II in the C-terminal hyperacidic tail which is essential for transactivation. EMBO J 11 (1992) 2211-2218
107. O'Mahony D.J., Xie W.Q., Smith S.D., Singer H.A., and Rothblum L.I. Differential phosphorylation and localization of the transcription factor UBF in vivo in response to serum deprivation. In vitro dephosphorylation of UBF reduces its transactivation properties. J Biol Chem 267 (1992) 35-38
108. Stefanovsky V.Y., Pelletier G., Hannan R., Gagnon-Kugler T., Rothblum L.I., and Moss T. An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF. Mol Cell 8 (2001) 1063-1073
109. Navolanic P.M., Steelman L.S., and McCubrey J.A. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (review). Int J Oncol 22 (2003) 237-252
110. Boxer L.M., and Dang C.V. Translocations involving c-myc and c-myc function. Oncogene 20 (2001) 5595-5610
111. Arabi A., Wu S., Ridderstrale K., Bierhoff H., Shiue C., Fatyol K., et al. c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nat Cell Biol 7 (2005) 303-310
112. Grandori C., Gomez-Roman N., Felton-Edkins Z.A., Ngouenet C., Galloway D.A., Eisenman R.N., et al. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol 7 (2005) 311-318
113. Iritani B.M., and Eisenman R.N. c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc Natl Acad Sci USA 96 (1999) 13180-13185
114. Kim S., Li Q., Dang C.V., and Lee L.A. Induction of ribosomal genes and hepatocyte hypertrophy by adenovirus-mediated expression of c-Myc in vivo. Proc Natl Acad Sci USA 97 (2000) 11198-11202
115. Thomas G. An encore for ribosome biogenesis in the control of cell proliferation. Nat Cell Biol 2 (2000) E71-E72
116. Barna M., Pusic A., Zollo O., Costa M., Kondrashov N., Rego E., et al. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 456 (2008) 971-975
117. Sherr C.J. Principles of tumor suppression. Cell 116 (2004) 235-246
118. Vousden K.H., and Lane D.P. p53 in health and disease. Nat Rev Mol Cell Biol 8 (2007) 275-283
119. Sherr C.J., and McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2 (2002) 103-112
120. Zhai W., and Comai L. Repression of RNA polymerase I transcription by the tumor suppressor p53. Mol Cell Biol 20 (2000) 5930-5938
121. Hannan K.M., Hannan R.D., Smith S.D., Jefferson L.S., Lun M., and Rothblum L.I. Rb and p130 regulate RNA polymerase I transcription: Rb disrupts the interaction between UBF and SL-1. Oncogene 19 (2000) 4988-4999
122. Voit R., Schafer K., and Grummt I. Mechanism of repression of RNA polymerase I transcription by the retinoblastoma protein. Mol Cell Biol 17 (1997) 4230-4237
123. Sutcliffe J.E., Brown T.R., Allison S.J., Scott P.H., and White R.J. Retinoblastoma protein disrupts interactions required for RNA polymerase III transcription. Mol Cell Biol 20 (2000) 9192-9202
124. Harbour J.W., and Dean D.C. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 14 (2000) 2393-2409
125. Cavanaugh A.H., Hempel W.M., Taylor L.J., Rogalsky V., Todorov G., and Rothblum L.I. Activity of RNA polymerase I transcription factor UBF blocked by Rb gene product. Nature 374 (1995) 177-180
126. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13 (1999) 1501-1512
127. Ayrault O., Andrique L., Fauvin D., Eymin B., Gazzeri S., and Seite P. Human tumor suppressor p14ARF negatively regulates rRNA transcription and inhibits UBF1 transcription factor phosphorylation. Oncogene 25 (2006) 7577-7586
128. Fatica A., and Tollervey D. Making ribosomes. Curr Opin Cell Biol 14 (2002) 313-318
129. Kondoh N., Shuda M., Tanaka K., Wakatsuki T., Hada A., and Yamamoto M. Enhanced expression of S8, L12, L23a, L27 and L30 ribosomal protein mRNAs in human hepatocellular carcinoma. Anticancer Res 21 (2001) 2429-2433
130. Ferrari S., Manfredini R., Tagliafico E., Rossi E., Donelli A., Torelli G., et al. Noncoordinated expression of S6, S11, and S14 ribosomal protein genes in leukemic blast cells. Cancer Res 50 (1990) 5825-5828
131. Naora H., Takai I., and Adachi M. Altered cellular responses by varying expression of a ribosomal protein gene: sequential coordination of enhancement and suppression of ribosomal protein S3a gene expression induces apoptosis. J Cell Biol 141 (1998) 741-753
132. Volarevic S., Stewart M.J., Ledermann B., Zilberman F., Terracciano L., Montini E., et al. Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6. Science 288 (2000) 2045-2047
133. Thomas G., Siegmann M., and Gordon J. Multiple phosphorylation of ribosomal protein S6 during transition of quiescent 3T3 cells into early G1, and cellular compartmentalization of the phosphate donor. Proc Natl Acad Sci USA 76 (1979) 3952-3956
134. Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., Hemmings B.A., et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 95 (1998) 13513-13518
135. Podsypanina K., Lee R.T., Politis C., Hennessy I., Crane A., Puc J., et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci USA 98 (2001) 10320-10325
136. Sekulic A., Hudson C.C., Homme J.L., Yin P., Otterness D.M., Karnitz L.M., et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 60 (2000) 3504-3513
137. Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4 (2002) 648-657
138. Stoneley M., and Willis A.E. Aberrant regulation of translation initiation in tumorigenesis. Curr Mol Med 3 (2003) 597-603
139. Pickering B.M., and Willis A.E. The implications of structured 5′ untranslated regions on translation and disease. Semin Cell Dev Biol 16 (2005) 39-47
140. Willis A.E. Translational control of growth factor and proto-oncogene expression. Int J Biochem Cell Biol 31 (1999) 73-86
141. Pelletier J., and Sonenberg N. Insertion mutagenesis to increase secondary structure within the 5′ noncoding region of a eukaryotic mRNA reduces translational efficiency. Cell 40 (1985) 515-526
142. Haupt Y., Maya R., Kazaz A., and Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
143. Kubbutat M.H., Jones S.N., and Vousden K.H. Regulation of p53 stability by Mdm2. Nature 387 (1997) 299-303
144. Uchida C., Miwa S., Kitagawa K., Hattori T., Isobe T., Otani S., et al. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J 24 (2005) 160-169
145. Zhang Z., and Zhang R. p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets 5 (2005) 9-20
146. Bond G.L., Hu W., and Levine A.J. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 5 (2005) 3-8
147. Landers J.E., Cassel S.L., and George D.L. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 57 (1997) 3562-3568
148. Capoulade C., Bressac-de Paillerets B., Lefrere I., Ronsin M., Feunteun J., Tursz T., et al. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene 16 (1998) 1603-1610
149. Brown C.Y., Mize G.J., Pineda M., George D.L., and Morris D.R. Role of two upstream open reading frames in the translational control of oncogene mdm2. Oncogene 18 (1999) 5631-5637
150. Jin X., Turcott E., Englehardt S., Mize G.J., and Morris D.R. The two upstream open reading frames of oncogene mdm2 have different translational regulatory properties. J Biol Chem 278 (2003) 25716-25721
151. Deng C.X. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 34 (2006) 1416-1426
152. Ford D., Easton D.F., Bishop D.T., Narod S.A., and Goldgar D.E. Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet 343 (1994) 692-695
153. Thompson D., and Easton D.F. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94 (2002) 1358-1365
154. Brose M.S., Rebbeck T.R., Calzone K.A., Stopfer J.E., Nathanson K.L., and Weber B.L. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94 (2002) 1365-1372
155. Taylor J., Lymboura M., Pace P.E., A'Hern R.P., Desai A.J., Shousha S., et al. An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. Int J Cancer 79 (1998) 334-342
156. Wilson C.A., Ramos L., Villasenor M.R., Anders K.H., Press M.F., Clarke K., et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 21 (1999) 236-240
157. Sobczak K., and Krzyzosiak W.J. Structural determinants of BRCA1 translational regulation. J Biol Chem 277 (2002) 17349-17358
158. Arrick B.A., Grendell R.L., and Griffin L.A. Enhanced translational efficiency of a novel transforming growth factor beta 3 mRNA in human breast cancer cells. Mol Cell Biol 14 (1994) 619-628
159. Arrick B.A., Lee A.L., Grendell R.L., and Derynck R. Inhibition of translation of transforming growth factor-beta 3 mRNA by its 5′ untranslated region. Mol Cell Biol 11 (1991) 4306-4313
160. Peng X., Mehta R.G., Tonetti D.A., and Christov K. Identification of novel RARbeta2 transcript variants with short 5′-UTRs in normal and cancerous breast epithelial cells. Oncogene 24 (2005) 1296-1301
161. Miyazaki K., Inoue S., Yamada K., Watanabe M., Liu Q., Watanabe T., et al. Differential usage of alternate promoters of the human stress response gene ATF3 in stress response and cancer cells. Nucleic Acids Res 37 (2009) 1438-1451
162. Yamaguchi-Kabata Y., Shimada M.K., Hayakawa Y., Minoshima S., Chakraborty R., Gojobori T., et al. Distribution and effects of nonsense polymorphisms in human genes. PLoS One 3 (2008) e3393
163. Gorski J.J., Kennedy R.D., Hosey A.M., and Harkin D.P. The complex relationship between BRCA1 and ERalpha in hereditary breast cancer. Clin Cancer Res 15 (2009) 1514-1518
164. Signori E., Bagni C., Papa S., Primerano B., Rinaldi M., Amaldi F., et al. A somatic mutation in the 5′UTR of BRCA1 gene in sporadic breast cancer causes down-modulation of translation efficiency. Oncogene 20 (2001) 4596-4600
165. Wang J., Lu C., Min D., Wang Z., and Ma X. A mutation in the 5′ untranslated region of the BRCA1 gene in sporadic breast cancer causes downregulation of translation efficiency. J Int Med Res 35 (2007) 564-573
166. Kim W.Y., and Sharpless N.E. The regulation of INK4/ARF in cancer and aging. Cell 127 (2006) 265-275
167. Liu L., Dilworth D., Gao L., Monzon J., Summers A., Lassam N., et al. Mutation of the CDKN2A 5′ UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 21 (1999) 128-132
168. Lu Q., Dobbs L.J., Gregory C.W., Lanford G.W., Revelo M.P., Shappell S., et al. Increased expression of delta-catenin/neural plakophilin-related armadillo protein is associated with the down-regulation and redistribution of E-cadherin and p120ctn in human prostate cancer. Hum Pathol 36 (2005) 1037-1048
169. Wang T., Chen Y.H., Hong H., Zeng Y., Zhang J., Lu J.P., et al. Increased nucleotide polymorphic changes in the 5′-untranslated region of delta-catenin (CTNND2) gene in prostate cancer. Oncogene 28 (2009) 555-564
170. Marsh S. Thymidylate synthase pharmacogenetics. Invest New Drugs 23 (2005) 533-537
171. Kawakami K., Salonga D., Park J.M., Danenberg K.D., Uetake H., Brabender J., et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 7 (2001) 4096-4101
172. Holcik M. Targeting translation for treatment of cancer-a novel role for IRES?. Curr Cancer Drug Targets 4 (2004) 299-311
173. Chappell S.A., LeQuesne J.P., Paulin F.E., deSchoolmeester M.L., Stoneley M., Soutar R.L., et al. A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: a novel mechanism of oncogene de-regulation. Oncogene 19 (2000) 4437-4440
174. Evans J.R., Mitchell S.A., Spriggs K.A., Ostrowski J., Bomsztyk K., Ostarek D., et al. Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo. Oncogene 22 (2003) 8012-8020
175. Shi Y., Frost P.J., Hoang B.Q., Benavides A., Sharma S., Gera J.F., et al. IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1. Cancer Res 68 (2008) 10215-10222
176. Holcik M., Yeh C., Korneluk R.G., and Chow T. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene 19 (2000) 4174-4177
177. Desplanques G., Giuliani N., Delsignore R., Rizzoli V., Bataille R., and Barille-Nion S. Impact of XIAP protein levels on the survival of myeloma cells. Haematologica 94 (2009) 87-93
178. Lopez de Silanes I., Quesada M.P., and Esteller M. Aberrant regulation of messenger RNA 3′-untranslated region in human cancer. Cell Oncol 29 (2007) 1-17
179. Dixon D.A., Tolley N.D., King P.H., Nabors L.B., McIntyre T.M., Zimmerman G.A., et al. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 108 (2001) 1657-1665
180. Young L.E., Sanduja S., Bemis-Standoli K., Pena E.A., Price R.L., and Dixon D.A. The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology 136 (2009) 1669-1679
181. Filipowicz W., Bhattacharyya S.N., and Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet 9 (2008) 102-114
182. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 136 (2009) 215-233
183. Ma X.M., and Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10 (2009) 307-318
184. Maira S.M., Stauffer F., Schnell C., and Garcia-Echeverria C. PI3K inhibitors for cancer treatment: where do we stand?. Biochem Soc Trans 37 (2009) 265-272
185. Guertin D.A., and Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 12 (2007) 9-22
186. Choo A.Y., and Blenis J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 8 (2009) 567-572
187. Franke T.F. PI3K/Akt: getting it right matters. Oncogene 27 (2008) 6473-6488
188. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006) 424-430
189. Hynes N.E., and MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21 (2009) 177-184
190. Ligresti G., Militello L., Steelman L.S., Cavallaro A., Basile F., Nicoletti F., et al. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle 8 (2009) 1352-1358
191. Yin Y., and Shen W.H. PTEN: a new guardian of the genome. Oncogene 27 (2008) 5443-5453
192. Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110 (2002) 177-189
193. Kim D.H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110 (2002) 163-175
194. Kim D.H., Sarbassov D.D., Ali S.M., Latek R.R., Guntur K.V., Erdjument-Bromage H., et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 11 (2003) 895-904
195. Foster D.A., and Toschi A. Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle 8 (2009) 1026-1029
196. van Slegtenhorst M., Nellist M., Nagelkerken B., Cheadle J., Snell R., van den Ouweland A., et al. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 7 (1998) 1053-1057
197. Avruch J., Long X., Lin Y., Ortiz-Vega S., Rapley J., Papageorgiou A., et al. Activation of mTORC1 in two steps: Rheb-GTP activation of catalytic function and increased binding of substrates to raptor. Biochem Soc Trans 37 (2009) 223-226
198. Kwiatkowski D.J. Tuberous sclerosis: from tubers to mTOR. Ann Hum Genet 67 (2003) 87-96
199. Ravitz M.J., Chen L., Lynch M., and Schmidt E.V. c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation. Cancer Res 67 (2007) 11209-11217
200. Schmidt E.V., Ravitz M.J., Chen L., and Lynch M. Growth controls connect: interactions between c-myc and the tuberous sclerosis complex-mTOR pathway. Cell Cycle 8 (2009) 1344-1351
201. Nardella C., Chen Z., Salmena L., Carracedo A., Alimonti A., Egia A., et al. Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev 22 (2008) 2172-2177
202. Mavrakis K.J., Zhu H., Silva R.L., Mills J.R., Teruya-Feldstein J., Lowe S.W., et al. Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev 22 (2008) 2178-2188
203. Connolly E., Braunstein S., Formenti S., and Schneider R.J. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol Cell Biol 26 (2006) 3955-3965
204. Vander Haar E., Lee S.I., Bandhakavi S., Griffin T.J., and Kim D.H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9 (2007) 316-323
205. Huang B., and Porter G. Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis. Acta Pharmacol Sin 26 (2005) 1253-1258
206. Madhunapantula S.V., Sharma A., and Robertson G.P. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res 67 (2007) 3626-3636
207. Johnson M.D., O'Connell M., Vito F., and Bakos R.S. Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas. J Neurooncol 92 (2009) 129-136
208. Wu X., Senechal K., Neshat M.S., Whang Y.E., and Sawyers C.L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 95 (1998) 15587-15591
209. Zhou X., Tan M., Stone Hawthorne V., Klos K.S., Lan K.H., Yang Y., et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10 (2004) 6779-6788
210. Akcakanat A., Sahin A., Shaye A.N., Velasco M.A., and Meric-Bernstam F. Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer 112 (2008) 2352-2358
211. Michlewski G., Sanford J.R., and Caceres J.F. The splicing factor SF2/ASF regulates translation initiation by enhancing phosphorylation of 4E-BP1. Mol Cell 30 (2008) 179-189
212. Karni R., de Stanchina E., Lowe S.W., Sinha R., Mu D., and Krainer A.R. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 14 (2007) 185-193
213. Ruggero D., and Pandolfi P.P. Does the ribosome translate cancer?. Nat Rev Cancer 3 (2003) 179-192
214. Nakamura J.L., Garcia E., and Pieper R.O. S6K1 plays a key role in glial transformation. Cancer Res 68 (2008) 6516-6523
215. Holz M.K., Ballif B.A., Gygi S.P., and Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123 (2005) 569-580
216. Shahbazian D., Roux P.P., Mieulet V., Cohen M.S., Raught B., Taunton J., et al. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 25 (2006) 2781-2791
217. van Gorp A.G., van der Vos K.E., Brenkman A.B., Bremer A., van den Broek N., Zwartkruis F., et al. AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B. Oncogene 28 (2009) 95-106
218. Dorrello N.V., Peschiaroli A., Guardavaccaro D., Colburn N.H., Sherman N.E., and Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314 (2006) 467-471
219. Carayol N., Katsoulidis E., Sassano A., Altman J.K., Druker B.J., and Platanias L.C. Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. J Biol Chem 283 (2008) 8601-8610
220. Waskiewicz A.J., Flynn A., Proud C.G., and Cooper J.A. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 16 (1997) 1909-1920
221. Pyronnet S., Imataka H., Gingras A.C., Fukunaga R., Hunter T., and Sonenberg N. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J 18 (1999) 270-279
222. Karreth F.A., and Tuveson D.A. Modelling oncogenic Ras/Raf signalling in the mouse. Curr Opin Genet Dev 19 (2009) 4-11
223. Wendel H.G., Silva R.L., Malina A., Mills J.R., Zhu H., Ueda T., et al. Dissecting eIF4E action in tumorigenesis. Genes Dev 21 (2007) 3232-3237
224. Topisirovic I., Ruiz-Gutierrez M., and Borden K.L. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res 64 (2004) 8639-8642
225. Bianchini A., Loiarro M., Bielli P., Busa R., Paronetto M.P., Loreni F., et al. Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells. Carcinogenesis 29 (2008) 2279-2288
226. Rouschop K.M., and Wouters B.G. Regulation of autophagy through multiple independent hypoxic signaling pathways. Curr Mol Med 9 (2009) 417-424
227. Liu L., Cash T.P., Jones R.G., Keith B., Thompson C.B., and Simon M.C. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 21 (2006) 521-531
228. DeYoung M.P., Horak P., Sofer A., Sgroi D., and Ellisen L.W. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 22 (2008) 239-251
229. Browne G.J., and Proud C.G. A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol Cell Biol 24 (2004) 2986-2997
230. Wang X., Li W., Williams M., Terada N., Alessi D.R., and Proud C.G. Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 20 (2001) 4370-4379
231. Gordan J.D., and Simon M.C. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 17 (2007) 71-77
232. Holcik M., and Sonenberg N. Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 6 (2005) 318-327
233. Fan D., Ma C., and Zhang H. The molecular mechanisms that underlie the tumor suppressor function of LKB1. Acta Biochim Biophys Sin (Shanghai) 41 (2009) 97-107
234. Koumenis C., Naczki C., Koritzinsky M., Rastani S., Diehl A., Sonenberg N., et al. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol Cell Biol 22 (2002) 7405-7416
235. Ameri K., and Harris A.L. Activating transcription factor 4. Int J Biochem Cell Biol 40 (2008) 14-21